$ACAD
ACADIA PHARMACEUTICALS INC

2013 Q2 Form 10-Q Financial Statement

#000119312513204467 Filed on May 07, 2013

View on sec.gov

Income Statement

Concept 2013 Q2 2013 Q1 2012 Q1
Revenue $451.0K $417.0K $450.0K
YoY Change -24.71% -7.33% 3.45%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.500M $2.200M $1.700M
YoY Change 56.25% 29.41% -10.53%
% of Gross Profit
Research & Development $7.112M $4.430M $5.021M
YoY Change 59.03% -11.77% 14.11%
% of Gross Profit
Depreciation & Amortization $12.00K
YoY Change
% of Gross Profit
Operating Expenses $9.608M $6.581M $6.681M
YoY Change 59.39% -1.5% 6.05%
Operating Profit -$9.157M -$6.164M -$6.231M
YoY Change 68.67% -1.08%
Interest Expense $76.00K $41.00K $0.00
YoY Change 660.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$9.100M -$6.100M -$6.200M
YoY Change 68.52% -1.61% 6.9%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$9.081M -$6.123M -$6.218M
YoY Change 67.58% -1.53% 6.6%
Net Earnings / Revenue -2013.53% -1468.35% -1381.78%
Basic Earnings Per Share
Diluted Earnings Per Share -$109.1K -$77.51K -$117.2K
COMMON SHARES
Basic Shares Outstanding 79.16M shares 78.76M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q2 2013 Q1 2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $205.5M $101.5M $25.90M
YoY Change 864.56% 291.89% -43.33%
Cash & Equivalents $24.25M $18.44M $5.558M
Short-Term Investments $181.2M $83.00M $20.40M
Other Short-Term Assets $1.300M $1.500M $500.0K
YoY Change 225.0% 200.0% -44.44%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $206.8M $103.0M $26.40M
YoY Change 849.53% 290.09% -43.23%
LONG-TERM ASSETS
Property, Plant & Equipment $92.00K $30.00K $100.0K
YoY Change 0.0% -70.0% -50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $56.00K $0.00
YoY Change 700.0% -100.0%
Total Long-Term Assets $148.0K $30.00K $100.0K
YoY Change 49.49% -70.0% -75.0%
TOTAL ASSETS
Total Short-Term Assets $206.8M $103.0M $26.40M
Total Long-Term Assets $148.0K $30.00K $100.0K
Total Assets $206.9M $103.0M $26.50M
YoY Change 845.91% 288.74% -43.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.177M $1.396M $1.000M
YoY Change 55.48% 39.6% -28.57%
Accrued Expenses $6.488M $4.159M $4.700M
YoY Change 24.17% -11.51% 9.3%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $7.776M $5.695M $6.400M
YoY Change 15.03% -11.02% 4.92%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $17.70M $17.70M $2.500M
YoY Change 637.5% 608.0% -3.85%
Total Long-Term Liabilities $17.70M $17.70M $2.500M
YoY Change 637.5% 608.0% -3.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.776M $5.695M $6.400M
Total Long-Term Liabilities $17.70M $17.70M $2.500M
Total Liabilities $25.40M $23.40M $8.900M
YoY Change 177.11% 162.92% 1.14%
SHAREHOLDERS EQUITY
Retained Earnings -$382.9M -$373.8M
YoY Change 6.81%
Common Stock $8.000K $7.000K
YoY Change 60.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $181.5M $79.66M $17.60M
YoY Change
Total Liabilities & Shareholders Equity $206.9M $103.0M $26.50M
YoY Change 845.91% 288.74% -43.5%

Cashflow Statement

Concept 2013 Q2 2013 Q1 2012 Q1
OPERATING ACTIVITIES
Net Income -$9.081M -$6.123M -$6.218M
YoY Change 67.58% -1.53% 6.6%
Depreciation, Depletion And Amortization $12.00K
YoY Change
Cash From Operating Activities -$5.440M -$6.585M -$5.230M
YoY Change 13.33% 25.91% 2.35%
INVESTING ACTIVITIES
Capital Expenditures -$60.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$98.55M -$33.09M $3.880M
YoY Change -1274.61% -952.84% -144.39%
Cash From Investing Activities -$98.61M -$33.09M $3.877M
YoY Change -1275.33% -953.39% -144.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $107.9M $208.0K $31.00K
YoY Change 570.97% -99.78%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 109.9M 208.0K 22.00K
YoY Change 183016.67% 845.45% -99.84%
NET CHANGE
Cash From Operating Activities -5.440M -6.585M -5.230M
Cash From Investing Activities -98.61M -33.09M 3.877M
Cash From Financing Activities 109.9M 208.0K 22.00K
Net Change In Cash 5.820M -39.46M -1.331M
YoY Change 59.45% 2864.91% 3227.5%
FREE CASH FLOW
Cash From Operating Activities -$5.440M -$6.585M -$5.230M
Capital Expenditures -$60.00K
Free Cash Flow -$5.380M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q1 us-gaap Stockholders Equity
StockholdersEquity
79662000
CY2013Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3500000
CY2013Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
88000
CY2013Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
79164885 shares
CY2012Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5558000
CY2013Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1522000
CY2013Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2013Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
26600000
CY2013Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
723000
CY2013Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
87769000
CY2013Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73455860 shares
CY2013Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
308000
CY2013Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1396000
CY2013Q1 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
83027000
CY2013Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
140000
CY2013Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-373843000
CY2013Q1 us-gaap Assets
Assets
103015000
CY2013Q1 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
27000
CY2013Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
103015000
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18436000
CY2013Q1 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
16000
CY2013Q1 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
101106000
CY2013Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73455860 shares
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
108590000
CY2013Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
15000
CY2013Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4159000
CY2013Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5695000
CY2013Q1 us-gaap Common Stock Value
CommonStockValue
7000
CY2013Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q1 us-gaap Assets Current
AssetsCurrent
102985000
CY2013Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2013Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2013Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30000
CY2013Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
453483000
CY2013Q1 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
87780000
CY2013Q1 acad Accrued Clinical Development Services
AccruedClinicalDevelopmentServices
3040000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6889000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
581000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
84984000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
146000
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
413000
CY2012Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
56382000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73334216 shares
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
364000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1375000
CY2012Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
50068000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
434000
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-367720000
CY2012Q4 us-gaap Assets
Assets
108590000
CY2012Q4 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
5000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57899000
CY2012Q4 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
5000
CY2012Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
107598000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73334216 shares
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4139000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5948000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Assets Current
AssetsCurrent
108548000
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
452693000
CY2012Q4 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
56382000
CY2012Q4 acad Accrued Clinical Development Services
AccruedClinicalDevelopmentServices
3216000
CY2013Q1 dei Trading Symbol
TradingSymbol
ACAD
CY2013Q1 dei Entity Registrant Name
EntityRegistrantName
ACADIA PHARMACEUTICALS INC
CY2013Q1 dei Amendment Flag
AmendmentFlag
false
CY2013Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2013Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2013Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013Q1 dei Document Type
DocumentType
10-Q
CY2013Q1 dei Document Period End Date
DocumentPeriodEndDate
2013-03-31
CY2013Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001070494
CY2013Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6164000
CY2013Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
21000
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
208000
CY2013Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6112000
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
582000
CY2013Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
21773000
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2013Q1 us-gaap Investment Income Net
InvestmentIncomeNet
41000
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6585000
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-33086000
CY2013Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-294000
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-39463000
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2151000
CY2013Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
941000
CY2013Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2013Q1 us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
-8000
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4430000
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
208000
CY2013Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
54867000
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
6581000
CY2013Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
5000
CY2013Q1 us-gaap Revenues
Revenues
417000
CY2013Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-145000
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
78748000 shares
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10718000 shares
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-6123000
CY2013Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
11000
CY2013Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
20000
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6231000
CY2012Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-926000
CY2012Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
31000
CY2012Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6221000
CY2012Q1 us-gaap Share Based Compensation
ShareBasedCompensation
413000
CY2012Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
7918000
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2012Q1 us-gaap Investment Income Net
InvestmentIncomeNet
13000
CY2012Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5230000
CY2012Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3877000
CY2012Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-72000
CY2012Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1331000
CY2012Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1660000
CY2012Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-4000
CY2012Q1 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
9000
CY2012Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-438000
CY2012Q1 us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
-9000
CY2012Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5021000
CY2012Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22000
CY2012Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
4050000
CY2012Q1 us-gaap Operating Expenses
OperatingExpenses
6681000
CY2012Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
21000
CY2012Q1 us-gaap Revenues
Revenues
450000
CY2012Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
79000
CY2012Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52903000 shares
CY2012Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11085000 shares
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-6218000
CY2012Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000
CY2012Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1189000

Files In Submission

Name View Source Status
0001193125-13-204467-index-headers.html Edgar Link pending
0001193125-13-204467-index.html Edgar Link pending
0001193125-13-204467.txt Edgar Link pending
0001193125-13-204467-xbrl.zip Edgar Link pending
acad-20130331.xml Edgar Link completed
acad-20130331.xsd Edgar Link pending
acad-20130331_cal.xml Edgar Link unprocessable
acad-20130331_def.xml Edgar Link unprocessable
acad-20130331_lab.xml Edgar Link unprocessable
acad-20130331_pre.xml Edgar Link unprocessable
d500777d10q.htm Edgar Link pending
d500777dex311.htm Edgar Link pending
d500777dex312.htm Edgar Link pending
d500777dex321.htm Edgar Link pending
d500777dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending